NPPA SETS NEW AFFORDABLE RANGE FOR DRUGS : CUTS OVER PRICING 

Date:

Share post:

NPPA SETS NEW AFFORDABLE RANGE FOR DRUGS : CUTS OVER PRICING 

PharmaGenDrx News Bureau – 05th August 2025, 

3:00 PM IST

 To ensure affordability and supply of essential medicines National Pharmaceutical Pricing Authority (NPPA) sets out to deliver a robust move in managing exploitation of prices. 

NPPA has recently issued three notices to tackle this situation, addressing ceiling price and retail price for over 40 drugs. This has been done under Drugs Price Control Order (DPCO) 2013. The notice issued on 1st August authorises the ceiling prices of scheduled drugs, for all manufacturers of scheduled and generic medicines have been conveyed to set or revise their ceiling prices according to the new mandate for commonly used drugs such as Ipratropium and Diltiazem. 

The next mandate addressed, retail prices for non scheduled new marketed drugs. This focused on the combined drug therapy strategies. 

Market based retailed price competition was addressed in another mandate, via market analysis. The objective of this mandate was to lower the price of drugs to an affordable  rate ensuring the fair pricing. This was done using Moving Annual Turn-over(MAT) and Price To Retailers (PTR) data. More than thirty such commonly used drugs were addressed and their percentage price was reduced such as Vit D3 oral drops. 

With the growing demands of safeguarding  public health, such steps taken by NPPA restores the faith of the residents in  the government, along with highlighting NPPA’s commitment towards curbing exploitation and improving transparency. 

By Sharon Bose and Arundhuti Chatterjee 

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Bhawanipur Global Campus Announces iNATCONPH 2026: A Global Platform for Pharmacy & Allied Health Research

Kolkata: Bhawanipur Global Campus has announced the 16th International Conference - iNATCONPH 2026, a prestigious international scientific conference...

Emcure Pharma Receives CDSCO Approval to Launch Poviztra®️ for Fatty Liver Disease Treatment

Emcure Pharmaceuticals Ltd  announced that its co-marketed semaglutide brand, Poviztra®, has received regulatory approval from the Central Drugs...

CDSCO Partners with THSTI to Strengthen Vaccine and Healthcare innovation

The Central Drugs Standard Control Organization (CDSCO), India’s national regulatory authority, and the Translational Health Science and Technology...

EMeRG Launches Hospital Intel Suite™️ to transform MedTech Market

EMeRG, a leading healthcare intelligence provider with over a decade of industry expertise,  announced the launch of Hospital...